Comparative Pharmacology
Head-to-head clinical analysis: FEMSTAT versus NATACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMSTAT versus NATACYN.
FEMSTAT vs NATACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FEMSTAT (butoconazole) is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
Butoconazole nitrate 2% vaginal cream: one applicatorful (approximately 5 g) intravaginally at bedtime for 3 days. Alternatively, butoconazole nitrate 2% single-dose vaginal cream: one applicatorful (approximately 5 g) intravaginally as a single dose.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
None Documented
None Documented
Terminal half-life: 6-9 hours; clinical context: supports twice-daily dosing for consistent therapeutic levels.
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites.
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Category C
Category C
Antifungal
Antifungal, Ophthalmic